Entera Bio appoints Laura Hamill and Juan Camilo Arjona Ferreira to board, effective Dec. 1
ENTX•Entera Bio appointed Laura Hamill and Juan Camilo Arjona Ferreira to its board, effective Dec. 1, 2026, and named four executives to medical and clinical development roles.
1. Board and executive appointments
Hamill, formerly Gilead’s worldwide commercial operations executive vice president, and Arjona Ferreira, Organon’s research and development head and chief medical officer, will join Entera Bio’s board on Dec. 1, 2026. The company also named Riccardo Paolo Camisasca chief medical officer, Michele McDermott senior vice president of medical affairs, Ofer Spiegelstein vice president and head of early clinical development, and Graziella Soulban vice president of clinical development and study lead.
